Alnylam Pharmaceuticals' (ALNY) Buy Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright reiterated a buy rating for Alnylam Pharmaceuticals (ALNY) with a price target of $570.00, indicating a potential upside of 27.74% from its current price.
• Several analysts have raised their price targets for Alnylam, with UBS increasing theirs to $550.00 and Piper Sandler to $449.00, further solidifying the stock's reputation as a buy.
• Alnylam reported a $0.32 earnings per share for the last quarter, exceeding estimates and reflecting a 17.3% revenue increase year-over-year, with total revenue hitting $773.69 million.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "buy" rating restated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $570.00 price target on the biopharmaceutical company's stock. HC Wainwright's target price would indicate a potential upside of 27.74% from the stock's current price.

A number of other equities research analysts have also issued reports on the stock. UBS Group raised their price target on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Piper Sandler boosted their price target on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Barclays upped their price target on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an "overweight" rating in a research report on Friday, August 1st. Bank of America lifted their price objective on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Finally, Truist Financial assumed coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They issued a "buy" rating and a $385.00 price target for the company. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $412.79.

Alnylam Pharmaceuticals Trading Down 0.1%

Shares of ALNY traded down $0.30 during trading hours on Tuesday, hitting $446.22. The company had a trading volume of 346,746 shares, compared to its average volume of 954,951. Alnylam Pharmaceuticals has a 52-week low of $205.87 and a 52-week high of $469.81. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock's 50 day moving average price is $377.23 and its 200 day moving average price is $304.58. The firm has a market cap of $58.49 billion, a P/E ratio of -180.66 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals's quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity

In other news, EVP Pushkal Garg sold 1,455 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the transaction, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,269,508.61. This represents a 6.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael W. Bonney sold 11,250 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the completion of the transaction, the director directly owned 16,804 shares in the company, valued at approximately $7,561,800. This represents a 40.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 57,594 shares of company stock valued at $25,551,456. Corporate insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in ALNY. Vanguard Group Inc. increased its position in Alnylam Pharmaceuticals by 1.8% in the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock worth $4,336,064,000 after purchasing an additional 240,534 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after purchasing an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD raised its position in Alnylam Pharmaceuticals by 5.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after purchasing an additional 185,783 shares during the period. Geode Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock valued at $779,857,000 after purchasing an additional 75,936 shares during the last quarter. Finally, Orbis Allan Gray Ltd boosted its stake in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock worth $691,771,000 after buying an additional 486,489 shares during the period. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.